Compare ATEN & NKTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEN | NKTR |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2014 | 1996 |
| Metric | ATEN | NKTR |
|---|---|---|
| Price | $30.09 | $70.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $26.33 | ★ $146.67 |
| AVG Volume (30 Days) | ★ 1.2M | 833.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | $235,429,000.00 | ★ $307,711,000.00 |
| Revenue This Year | $13.02 | N/A |
| Revenue Next Year | $10.82 | N/A |
| P/E Ratio | $169.29 | ★ N/A |
| Revenue Growth | 2.36 | ★ 86.00 |
| 52 Week Low | $16.52 | $21.02 |
| 52 Week High | $38.49 | $109.00 |
| Indicator | ATEN | NKTR |
|---|---|---|
| Relative Strength Index (RSI) | 26.35 | 54.99 |
| Support Level | $17.00 | $64.28 |
| Resistance Level | $32.95 | $76.78 |
| Average True Range (ATR) | 1.54 | 3.57 |
| MACD | -0.98 | 0.17 |
| Stochastic Oscillator | 0.00 | 66.12 |
A10 Networks Inc is a provider of secure application and network infrastructure solutions for enterprises and service providers across on-premises, hybrid cloud, and distributed environments. The company's offerings include application delivery and traffic management, distributed denial-of-service (DDoS) protection, application and API security, and centralized management. It serves customers across multiple industries, including telecommunications, technology, financial services, public sector, industrial, retail, gaming, and education. The majority of the company's revenue is derived from the sale of secure networking and cybersecurity solutions and related maintenance and support services.
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.